Search Results

Johnson & Johnson submits regulatory applications to European Medicines Agency for TREMFYA® (guselkumab) for treatment of patients with ulcerative colitis and Crohn’s disease

Janssen-Cilag International NV, a Johnson & Johnson company, today announced it has submitted applications to the European Medicines Agency to include the treatment of adult patients with moderately to severely active ulcerative colitis and moderately to severely active Crohn’s disease.

May 1, 2024

·

14 min read

MustGrow and Janssen PMP, a division of Janssen Pharmaceutica NV, Announce Significant Project Expansion

MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company” or “MustGrow”), and Janssen PMP, a division of Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (“Janssen PMP”) are pleased to announce a significant expansion to their existing Exclusive Evaluation and Option Agreement

September 6, 2023

·

9 min read

MustGrow and Janssen PMP, a Division of Janssen Pharmaceutica NV, Extend Exclusive Global Partnership

MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company”, “MustGrow”), and JANSSEN PMP, a division of Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson

May 23, 2023

·

7 min read

Business

Predicine Announces Collaboration with Janssen to Develop PredicineCARE™ as a Companion Diagnostic Assay in Localized Bladder Cancer

Predicine, Inc., a leading molecular insights company, announced a collaboration with Janssen Pharmaceutica NV, a Johnson & Johnson company.

January 8, 2024

·

2 min read

Press Releases

Vivoryon Therapeutics N.V. to Host Virtual R&D Update with KOL Speakers on February 18, 2025

February 11, 2025

·

4 min read

Press Releases

Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Update with KOL Speakers

February 19, 2025

·

8 min read

Press Releases

Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements

January 27, 2025

·

3 min read

Press Releases

QIAGEN N.V. to Release Results for Q4 2024 and Hold Webcast

January 15, 2025

·

1 min read

Press Releases

Johnson & Johnson’s DARZALEX® (daratumumab) subcutaneous-based regimen receives positive CHMP opinion for patients with newly diagnosed multiple myeloma, regardless of transplant eligibility

March 3, 2025

·

13 min read

Janssen Affiliate Cilag GmbH International Discontinues Collaboration and License Agreement with argenx for Cusatuzumab

Cilag GmbH International, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced its decision not to continue the collaboration and license agreement with argenx for cusatuzumab, an investigational therapeutic antibody that targets CD70.

June 7, 2021

·

3 min read